The pharmacokinetics and tolerability of an intravenous infusion of the new hydroxyethyl starch 130/0.4 (6%, 500 mL) in mild-to-severe renal impairment

Anesthesia and Analgesia

Volumn 95, Issue 3, 2002, Pages 544-551

  Jungheinrich, Cornelius ^a   Scharpf, Roland ^a   Wargenau, Manfred ^a   Bepperling, Frank ^a   Baron, Jean François ^a  

^a Fresenius Kabi Deutschland GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLASE; HETASTARCH;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CALCULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CORRELATION ANALYSIS; CREATININE CLEARANCE; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ASSAY; FEMALE; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; MALE; MICTURITION; MOLECULAR WEIGHT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REGRESSION ANALYSIS; URINALYSIS; URINARY EXCRETION;

EID: 0036711873     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/00000539-200209000-00007     Document Type: Article

References (28)

1. Intestinal elimination of hydroxyethyl starch?
2. HES 130/0.4, a new HES specification: Pharmacokinetics after multiple infusions of 10% solutions in healthy volunteers
3. HES 130/0.4, a new HES specification: Tissue storage after multiple infusions in rats
4. Studies on hydroxyethyl starch. Part II. Changes of the molecular weight distribution for hydroxyethyl starch types 450/0.7, 450/0.5, 450/0.3, 300/0.4, 200/0.7, 200/0.5, 200/0.3, and 200/0.1 after infusion in serum and urine in volunteers
5. Einfluss der molekuel-struktur von hydroxyaethylstaerke auf die eliminationskinetik und die fliessfaehigkeit des blutes bei probanden
6. HES 200/0.5 is not HES 200/0.5: Influence of the C2/C6 hydroxyethylation ratio of hydroxyethyl starch (HES) on hemorheology, coagulation and elimination kinetics
7. Volume therapy with a new hydroxyethyl starch solution in cardiac surgical patients before cardiopulmonary bypass
8. A novel hydroxyethyl starch (Voluven®) for effective perioperative plasma volume substitution in cardiac surgery
9. Cardiovascular and metabolic response to acute normovolemic anemia: Effects of anesthesia
10. Voluven, a lower substituted novel hydroxyethyl starch (HES 130/0.4), causes fewer effects on coagulation in major orthopedic surgery than HES 200/0.5
11. The influence of intravascular volume therapy with a new hydroxyethyl starch preparation (6% HES 130/0.4) on coagulation in patients undergoing major abdominal surgery
12. Influence of a new hydroxyethylstarch preparation (HES 130/0.4) on coagulation in cardiac surgical patients
13. Colloids versus crystalloids and tissue oxygen tension in patients undergoing major abdominal surgery
14. Pharmacokinetics and tolerability of a new hydroxyethyl starch (HES) specification [HES(130/0.4)] after single-dose infusion of 6% or 10% solutions in healthy volunteers
15. Macroamylasemia induced by hydroxyethyl starch: Confirmation by gel filtration analysis of serum and urine
16. Hydroxyethyl starch: An agent for hypovolemic shock treatment
17. Hydroxyethyl starch in balanced electrolyte solution (Hextend): Pharmacokinetic and pharmacodynamic profiles in healthy volunteers
18. Effect of a new hydroxyethyl starch (HES) specification [6% HES(130/0.4)] on blood and plasma volumes after bleeding in 12 healthy male volunteers
19. Acetylstaerke als volumenersatz, eine moegliche alternative zu HES
20. Hydroxyethyl starch in patients with decreased kidney function
21. Hydroxyethyl starch (HES) does not directly affect renal function in patients with no prior renal impairment
22. The influence of different intravascular volume replacement regimens on renal function in the elderly
23. Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: A multicentre randomised study
24. Hydroxyethylstarch as a risk factor for acute renal failure in severe sepsis
25. Coronary artery bypass grafting in patients with mild renal insufficiency
26. Acute renal failure following cardiac surgery
27. Renal dysfunction after myocardial revascularization: Risk factors, adverse outcomes, and hospital resource utilization. The Multicenter Study of Perioperative Ischemia Research Group